Actively Recruiting
Efficacy of 0.5% Topical Timolol Eye Drops in Treating Post-Inflammatory Erythema After Acne Vulgaris Compared With Intense Pulsed Light Therapy
Led by Pham Ngoc Thach University of Medicine · Updated on 2026-04-01
60
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the effectiveness and safety of topical 0.5% timolol eye drops in treating post-inflammatory erythema (PIE), a common red skin condition that follows acne vulgaris. The study compares timolol's effects with those of intense pulsed light (IPL) therapy, which is currently used but can be costly and require special equipment. The goal is to find a more affordable and accessible treatment option for managing PIE after acne. Participants will be randomly assigned to one of two groups. One group will apply timolol 0.5% ophthalmic solution twice daily to the affected skin areas for four weeks. The other group will receive a single session of IPL therapy targeting the erythema lesions at the start of the treatment period. Both groups will have their skin condition monitored and evaluated throughout the study. During the study, researchers will assess the severity of erythema using a clinical scale and count the number of lesions at baseline, day 14, and day 28. They will also monitor participants for any local or systemic side effects. Patient satisfaction with the aesthetic results will be measured at day 28. The study is expected to provide detailed information on how each treatment affects post-inflammatory erythema over the one-month period.
CONDITIONS
Brief Title
Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 12 years or older with a history of acne vulgaris
- Clinically diagnosed with post-inflammatory erythema secondary to acne vulgaris
- Willing and able to provide informed consent or assent with parental/guardian consent if under 18 years old
You will not qualify if you...
- Refusal to participate or inability to comply with study procedures or follow-up
- Presence of post-inflammatory hyperpigmentation at the study site
- Other skin conditions affecting the treatment area such as atopic dermatitis, rosacea, or lupus erythematosus
- Known allergy or adverse reaction to timolol or beta-blockers
- Pregnant or breastfeeding women
- History of cardiovascular or respiratory conditions contraindicating beta-blocker use, including asthma, atrioventricular block, bradycardia below 50 beats per minute, or low blood pressure
- Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants receive either topical timolol 0.5% ophthalmic solution applied twice daily for 4 weeks or a single session of Intense Pulsed Light therapy targeting post-inflammatory erythema lesions.
Baseline visit and 2 follow-up visits at Day 14 and Day 28
Trial Site Locations
Total: 1 location
1
Ho Chi Minh City Hospital of Dermato-Venereology
Ho Chi Minh City, Vietnam
Actively Recruiting
Research Team
P
Pham Duc Vu
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here